CITIC Med Fund

CITIC Med Fund operates as a specialized healthcare investment vehicle under CITIC Private Equity, the alternative asset management division of CITIC Group. CITIC Group is one of China's largest state-owned conglomerates, with businesses spanning financial services, resources, manufacturing, and real estate. The Med Fund benefits from the parent company's balance sheet, government relationships, and sector expertise.

The fund primarily invests across pharmaceuticals, medical devices, diagnostics, and healthcare services within China. Based on public reporting and the firm's own communications, the strategy has included traditional Chinese medicine producers, in-vitro diagnostics companies, and regional hospital networks. The firm pursues a thesis-driven approach centered on platforms that can benefit from China's healthcare regulatory reforms.

CITIC Med Fund makes direct equity investments into portfolio companies. As a captive private equity arm within a larger conglomerate, its model centers on originating and executing its own control and structured minority deals rather than allocating to external fund managers. It does not operate as a fund-of-funds.

The fund's mandate is focused on healthcare companies operating predominantly within mainland China. Its Shanghai headquarters positions it close to both China's pharmaceutical R&D cluster and its most developed hospital markets, though the firm evaluates opportunities across multiple Chinese provinces.

Deal origination is supported by CITIC Group's extensive government and commercial networks, allowing the Med Fund to access proprietary opportunities including state-owned enterprise carve-outs, provincial-level healthcare privatization deals, and new-product licensing arrangements. This sourcing approach differentiates it from independent financial sponsors competing in broad auction processes.